Robert J. Hopkins, MD, MPH & TM, FACP, FIDSA, is a highly regarded medical and research professional in infectious diseases with over 25 years of industry experience
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced the appointment of Evan Loh, M.D., CEO of Paratek Pharmaceuticals, Inc. (NASDAQ: PRTK), Jonathan Leff, Partner at Deerfield Management, and Jana Jensen, Ph.D., Chief Operating Officer at Deerfield Discovery and Development, to the company’s Board of Directors.
Adaptive Phage Therapeutics Announces Collaboration with Oyster Point Pharma to Target Ophthalmic Diseases
Adaptive Phage Therapeutics, Inc. (“APT”), a clinical-stage biotechnology company dedicated to providing therapies to treat infectious diseases, today announced a newly-formed research collaboration with Oyster Point Pharma, Inc. (Nasdaq: OYST) for developing therapies, using APT’s PhageBank™ technology, potentially targeting multiple ophthalmic diseases.
Gaithersburg’s Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis
Adaptive Phage Therapeutics Announces FDA Clearance of IND Application for PhageBank™ in Treatment of Diabetic Foot Osteomyelitis GAITHERSBURG, Md.–(BUSINESS WIRE)–Adaptive Phage Therapeutics (APT), a clinical-stage biotechnology company dedicated to advancing therapies [….]
Biopharma and Life Science companies in the BioHealth Capital Region are known for their work with cutting edge technologies such as gene and cell therapies. Those strengths were on display at the 6th annual BioHealth Capital Region Forum.
The COVID-19 Pandemic didn’t stop the Maryland Tech Council from holding their 32nd Annual Industry awards. Taking this event online, MTC continued via a live virtual broadcast to recognize the top Life Sciences and Tech Companies in Maryland.
The Bacteriophage (Phage) Therapy (PT) market is growing rapidly in the U.S. The rise of antibiotic resistant bacteria and multidrug-resistant bacteria (MDRs) across the globe has increased the value and industry acceptance of a phage approach, which can help combat bacteria that cannot be effectively treated by antibiotics. What’s more, the phage modality is a great fit for targeted personalized medicine approaches.
Whether it’s “Mom and Pop” retail storefronts, family-run home services companies or life science companies developing innovative, life saving products, family owned-and-operated businesses are the lifeblood of the global economy.
Maryland is the epicenter of biotech and life science innovation in the BioHealth Capital Region (BHCR). The state is home to a burgeoning life science ecosystem, including a rapidly growing cell and gene therapy industry, a robust and growing advanced biomanufacturing environment, and a deep network of leading research universities and critical government life science research entities.
COVID-19 Vaccine Progress from 14 BioHealth Capital Region Companies